Published in J Mol Med (Berl) on December 04, 2009
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Is AD a homogeneous nosologic entity? Yes. J Neural Transm (Vienna) (2013) 1.39
Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol Disord Drug Targets (2010) 1.33
Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem (2011) 1.22
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Tau, prions and Aβ: the triad of neurodegeneration. Acta Neuropathol (2010) 0.99
A mutant prion protein sensitizes neurons to glutamate-induced excitotoxicity. J Neurosci (2013) 0.95
Genetic cross-interaction between APOE and PRNP in sporadic Alzheimer's and Creutzfeldt-Jakob diseases. PLoS One (2011) 0.89
Neuroimmunoendocrine regulation of the prion protein in neutrophils. J Biol Chem (2012) 0.87
Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation. Neurobiol Aging (2012) 0.87
Pathogenic prions deviate PrP(C) signaling in neuronal cells and impair A-beta clearance. Cell Death Dis (2013) 0.87
Neuroprotective role of PrPC against kainate-induced epileptic seizures and cell death depends on the modulation of JNK3 activation by GluR6/7-PSD-95 binding. Mol Biol Cell (2011) 0.86
The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers. FASEB J (2013) 0.86
Healthy goats naturally devoid of prion protein. Vet Res (2012) 0.84
Regulation of PrP(C) signaling and processing by dimerization. Front Cell Dev Biol (2014) 0.83
Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease. J Biol Chem (2011) 0.83
Amyloid beta precursor protein and prion protein have a conserved interaction affecting cell adhesion and CNS development. PLoS One (2012) 0.82
Cellular prion protein (PrP(C)) and its role in stress responses. Int J Clin Exp Med (2015) 0.81
Immunomodulation for prion and prion-related diseases. Expert Rev Vaccines (2010) 0.80
Myelin damage due to local quantitative abnormalities in normal prion levels: evidence from subacute combined degeneration and multiple sclerosis. J Neurol (2013) 0.75
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Mice devoid of PrP are resistant to scrapie. Cell (1993) 11.46
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci (2001) 6.61
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature (2009) 6.17
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science (2005) 5.52
The most infectious prion protein particles. Nature (2005) 5.37
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science (2003) 4.57
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res (1991) 4.31
Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature (1996) 4.25
Prion protein biology. Cell (1998) 4.20
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem (2009) 3.66
Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell (1998) 3.59
Mammalian prion biology: one century of evolving concepts. Cell (2004) 3.46
Signal transduction through prion protein. Science (2000) 3.09
An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat (1995) 3.07
Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A (2009) 3.06
Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem (2008) 2.90
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
The exceptionally small size of the scrapie agent. Biochem Biophys Res Commun (1966) 2.83
Purified prion proteins and scrapie infectivity copartition into liposomes. Proc Natl Acad Sci U S A (1987) 2.61
The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J (2008) 2.43
Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J (2007) 2.27
Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A (2009) 2.27
Prions prevent neuronal cell-line death. Nature (1999) 2.13
Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105-125. EMBO J (2007) 2.12
The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta (2007) 2.09
Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci U S A (2007) 2.05
Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science (2004) 2.00
PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol (2003) 1.94
Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet (1998) 1.93
Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull (2003) 1.89
Scrapie prion liposomes and rods exhibit target sizes of 55,000 Da. Virology (1988) 1.85
Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nat Biotechnol (2004) 1.63
Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol (2004) 1.52
Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis (2005) 1.45
Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci (2008) 1.44
Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology (2004) 1.39
Unusual resistance to ionizing radiation of the viruses of kuru, Creutzfeldt-Jakob disease, and scrapie. Proc Natl Acad Sci U S A (1978) 1.37
Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain (2008) 1.30
Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. J Am Chem Soc (2009) 1.30
Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke (2006) 1.29
Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci (2007) 1.28
NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A (2003) 1.28
Gerstmann-Sträussler-Scheinker disease and the Indiana kindred. Brain Pathol (1995) 1.25
The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol (2007) 1.25
Gerstmann-Sträussler-Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family. Neurology (1989) 1.22
Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J Neurosci (2005) 1.21
Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO J (2008) 1.18
A 60-kDa prion protein (PrP) with properties of both the normal and scrapie-associated forms of PrP. J Biol Chem (1995) 1.15
The prion gene is associated with human long-term memory. Hum Mol Genet (2005) 1.14
A monomer-dimer equilibrium of a cellular prion protein (PrPC) not observed with recombinant PrP. J Biol Chem (2000) 1.05
The role of PrP in pathogenesis of experimental scrapie. Cold Spring Harb Symp Quant Biol (1996) 1.01
Familial Gerstmann-Sträussler-Scheinker disease with neurofibrillary tangles. Mol Neurobiol (1994) 1.01
Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis (2009) 0.98
Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiol Aging (2007) 0.96
Proteomic profiling of PrP27-30-enriched preparations extracted from the brain of hamsters with experimental scrapie. Proteomics (2009) 0.93
Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-Beta and prion peptides: implications for Alzheimer's disease and prion-related encephalopathies. Cell Mol Neurobiol (2007) 0.92
Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis (2008) 0.92
Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt-Jakob Disease phenotype. Neurosci Lett (2001) 0.89
Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neurosci Lett (1995) 0.86
Modeling a prion protein dimer: predictions for fibril formation. Biochem Biophys Res Commun (2000) 0.83
Early cognitive decline is associated with prion protein codon 129 polymorphism. Ann Neurol (2003) 0.83
In vivo behavior of muscle fascicles and tendinous tissues in human tibialis anterior muscle during twitch contraction. J Biomech (2007) 0.78
ApoE distribution and family history in genetic prion diseases in Germany. J Mol Neurosci (2007) 0.78
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Axon regeneration in young adult mice lacking Nogo-A/B. Neuron (2003) 4.23
Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science (2005) 4.15
Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science (2002) 3.50
Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron (2010) 3.44
Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci (2010) 3.36
An unbiased expression screen for synaptogenic proteins identifies the LRRTM protein family as synaptic organizers. Neuron (2009) 3.34
Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature (2002) 3.33
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Rho kinase inhibition enhances axonal regeneration in the injured CNS. J Neurosci (2003) 2.76
Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron (2004) 2.76
Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci (2004) 2.67
A new role for Nogo as a regulator of vascular remodeling. Nat Med (2004) 2.63
Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci (2004) 2.29
Can regenerating axons recapitulate developmental guidance during recovery from spinal cord injury? Nat Rev Neurosci (2006) 2.28
Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci (2003) 2.23
RGM and its receptor neogenin regulate neuronal survival. Nat Cell Biol (2004) 2.14
The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci (2003) 2.11
Extracellular regulators of axonal growth in the adult central nervous system. Philos Trans R Soc Lond B Biol Sci (2006) 2.10
Small proline-rich repeat protein 1A is expressed by axotomized neurons and promotes axonal outgrowth. J Neurosci (2002) 2.01
Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci (2002) 1.96
Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J Neurosci (2008) 1.96
Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. J Neurosci (2007) 1.88
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
MAG and OMgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma. J Neurosci (2010) 1.86
Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J (2003) 1.78
The Nogo-Nogo receptor pathway limits a spectrum of adult CNS axonal growth. J Neurosci (2006) 1.77
Neogenin mediates the action of repulsive guidance molecule. Nat Cell Biol (2004) 1.77
Axonal growth therapeutics: regeneration or sprouting or plasticity? Trends Neurosci (2008) 1.66
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Functional axonal regeneration through astrocytic scar genetically modified to digest chondroitin sulfate proteoglycans. J Neurosci (2007) 1.64
The reticulons: a family of proteins with diverse functions. Genome Biol (2007) 1.62
Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci (2002) 1.55
Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci (2003) 1.52
Delayed Nogo receptor therapy improves recovery from spinal cord contusion. Ann Neurol (2006) 1.44
The CRMP family of proteins and their role in Sema3A signaling. Adv Exp Med Biol (2007) 1.43
Transgenic inhibition of Nogo-66 receptor function allows axonal sprouting and improved locomotion after spinal injury. Mol Cell Neurosci (2005) 1.43
Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2010) 1.42
Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells. Proc Natl Acad Sci U S A (2006) 1.39
ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist (2007) 1.38
The N-terminal domain of Nogo-A inhibits cell adhesion and axonal outgrowth by an integrin-specific mechanism. J Neurosci (2008) 1.38
Axon regeneration in the peripheral and central nervous systems. Results Probl Cell Differ (2009) 1.37
LGI1-associated epilepsy through altered ADAM23-dependent neuronal morphology. Mol Cell Neurosci (2009) 1.32
Structural bases for CRMP function in plexin-dependent semaphorin3A signaling. EMBO J (2003) 1.29
Combination of NEP 1-40 treatment and motor training enhances behavioral recovery after a focal cortical infarct in rats. Stroke (2010) 1.25
Targeting the Nogo receptor to treat central nervous system injuries. Nat Rev Drug Discov (2003) 1.25
RanBPM contributes to Semaphorin3A signaling through plexin-A receptors. J Neurosci (2006) 1.24
Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J Neurosci (2006) 1.24
Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord. J Neurosci (2009) 1.22
Recovery from chronic spinal cord contusion after Nogo receptor intervention. Ann Neurol (2011) 1.18
Anatomical plasticity of adult brain is titrated by Nogo Receptor 1. Neuron (2013) 1.18
Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice. J Neurosci (2006) 1.16
Response to correspondence: Kim et al., "axon regeneration in young adult mice lacking Nogo-A/B." Neuron 38, 187-199. Neuron (2007) 1.15
Inosine augments the effects of a Nogo receptor blocker and of environmental enrichment to restore skilled forelimb use after stroke. J Neurosci (2011) 1.14
Nogo-A interacts with the Nogo-66 receptor through multiple sites to create an isoform-selective subnanomolar agonist. J Neurosci (2005) 1.12
Myelin associated inhibitors: a link between injury-induced and experience-dependent plasticity. Exp Neurol (2011) 1.12
Release of MICAL autoinhibition by semaphorin-plexin signaling promotes interaction with collapsin response mediator protein. J Neurosci (2008) 1.12
Reticulon-4A (Nogo-A) redistributes protein disulfide isomerase to protect mice from SOD1-dependent amyotrophic lateral sclerosis. J Neurosci (2009) 1.11
Characterization of myelin ligand complexes with neuronal Nogo-66 receptor family members. J Biol Chem (2006) 1.07
Ibuprofen enhances recovery from spinal cord injury by limiting tissue loss and stimulating axonal growth. J Neurotrauma (2009) 1.03
Cartilage acidic protein-1B (LOTUS), an endogenous Nogo receptor antagonist for axon tract formation. Science (2011) 1.03
Myelin-derived ephrinB3 restricts axonal regeneration and recovery after adult CNS injury. Proc Natl Acad Sci U S A (2012) 1.02
Vps10 family proteins and the retromer complex in aging-related neurodegeneration and diabetes. J Neurosci (2012) 1.02
Genetic deletion and pharmacological inhibition of Nogo-66 receptor impairs cognitive outcome after traumatic brain injury in mice. J Neurotrauma (2010) 1.00
Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain (2012) 0.98
Effect of combined treatment with methylprednisolone and soluble Nogo-66 receptor after rat spinal cord injury. Eur J Neurosci (2005) 0.98
Regulating axon growth within the postnatal central nervous system. Semin Perinatol (2004) 0.98
Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion (2012) 0.97
Nogo and the Nogo-66 receptor. Prog Brain Res (2002) 0.97
A multi-domain fragment of Nogo-A protein is a potent inhibitor of cortical axon regeneration via Nogo receptor 1. J Biol Chem (2011) 0.97
Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease. Arch Neurol (2009) 0.96
Axonal regeneration induced by blockade of glial inhibitors coupled with activation of intrinsic neuronal growth pathways. Exp Neurol (2012) 0.96
Selective temporal and regional alterations of Nogo-A and small proline-rich repeat protein 1A (SPRR1A) but not Nogo-66 receptor (NgR) occur following traumatic brain injury in the rat. Exp Neurol (2006) 0.95
Nogo-C is sufficient to delay nerve regeneration. Mol Cell Neurosci (2003) 0.94
PlexinA2 limits recovery from corticospinal axotomy by mediating oligodendrocyte-derived Sema6A growth inhibition. Mol Cell Neurosci (2012) 0.92
Membrane-type matrix metalloproteinase-3 regulates neuronal responsiveness to myelin through Nogo-66 receptor 1 cleavage. J Biol Chem (2011) 0.91
A neutralizing anti-Nogo66 receptor monoclonal antibody reverses inhibition of neurite outgrowth by central nervous system myelin. J Biol Chem (2004) 0.90
Regenerating nerves follow the road more traveled. Nat Neurosci (2002) 0.90
Nogo receptor interacts with brain APP and Abeta to reduce pathologic changes in Alzheimer's transgenic mice. Curr Alzheimer Res (2007) 0.89
Diffusion tensor imaging as a predictor of locomotor function after experimental spinal cord injury and recovery. J Neurotrauma (2014) 0.87
Nogo receptor deletion and multimodal exercise improve distinct aspects of recovery in cervical spinal cord injury. J Neurotrauma (2010) 0.86
Differential but competitive binding of Nogo protein and class i major histocompatibility complex (MHCI) to the PIR-B ectodomain provides an inhibition of cells. J Biol Chem (2011) 0.86
Human NgR-Fc decoy protein via lumbar intrathecal bolus administration enhances recovery from rat spinal cord contusion. J Neurotrauma (2014) 0.83
Functional MRI and other non-invasive imaging technologies: providing visual biomarkers for spinal cord structure and function after injury. Exp Neurol (2008) 0.81
Neuroscience. Lynx for braking plasticity. Science (2010) 0.78
Multimodal exercises simultaneously stimulating cortical and brainstem pathways after unilateral corticospinal lesion. Brain Res (2013) 0.77
Delayed amyloid plaque deposition and behavioral deficits in outcrossed AβPP/PS1 mice. J Comp Neurol (2013) 0.77
No association between schizophrenia and polymorphisms of the PlexinA2 gene in Chinese Han Trios. Schizophr Res (2007) 0.76
Nogo-A marks motor neuron disease. Ann Neurol (2007) 0.76
Serum Nogo-A levels are not elevated in amyotrophic lateral sclerosis patients. Biomarkers (2009) 0.75